2.02
+0.3443(+20.56%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.85 |
| Day High | 2.16 |
| Day Low | 1.71 |
| 52-Week High | 4.32 |
| 52-Week Low | 0.53 |
| Volume | 18.57M |
| Average Volume | 6.8M |
| Market Cap | 18.42M |
| PE | -0.63 |
| EPS | -3.21 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 0.95 |
| Change | 0.34 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of October 08, 2025 at a share price of $2.14. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.74 as of October 08, 2025 at a share price of $2.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
GlobeNewswire Inc.
Oct 02, 2025 8:05 PM GMT
Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands Capital, Deep Track Capital, Janus Henderson Inves
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Oct 01, 2025 1:20 PM GMT
Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune,
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
GlobeNewswire Inc.
Sep 18, 2025 8:05 PM GMT
Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflamma